Oxidative stress markers in intestinal mucosa of Tunisian inflammatory bowel disease patients.

Dorra Bouzid, Bochra Gargouri, Riadh Ben Mansour, Ali Amouri, Nabil Tahri, Saloua Lassoued, Hatem Masmoudi
Author Information
  1. Dorra Bouzid: Department of Immunology, Medicine School and Habib Bourguiba Hospital, Sfax, Tunisia. dorra-ing@voila.fr

Abstract

BACKGROUND / AIMS: Inflammatory bowel diseases (IBDs), Crohn's disease (CrD) and ulcerative colitis (UC), are chronic gastrointestinal inflammatory disorders. The precise etiology of IBD remains unclear, and it is thought that interactions among various factors, including, genetic factors, the host immune system and environmental factors, cause disruption of intestinal homeostasis, leading to dysregulated inflammatory responses of the gut. As inflammation is intimately related to formation of reactive intermediates, including, reactive oxygen species, oxidative stress has been proposed as a mechanism underlying the pathophysiology of IBD. The purpose of this study is to examine the lipid peroxidation, protein oxidation and anti-oxidative profile in Tunisian IBD.
MATERIALS AND METHODS: Malondialdehyde (MDA), conjugated dienes (CD), protein thiol levels, as well as the catalase (CAT) activity were evaluated in intestinal biopsies of 17 patients affected by IBD (12 CrD and 5 UC) and 12 healthy control individuals.
RESULTS: Oxidative stress was confirmed in these two types of disease biopsies as compared to controls. MDA and CD levels were significantly increased in both UC and CrD patients' biopsies as compared to controls' biopsies ( P < 0.001). CAT activity was similar in UC and CrD biopsies' and was not significantly increased in IBD patients' biopsies compared with controls' biopsies ( P > 0.05). Anon-significant decrease in thiol (SH) level was observed in both UC and CrD patients' biopsies compared with controls' biopsies ( P > 0.05).
CONCLUSION: Increased levels of MDA and CD in IBD patients' biopsies underline the implication of oxidative stress in the physiopathology of IBD.

References

  1. Free Radic Biol Med. 2002 Aug 1;33(3):311-22 [PMID: 12126753]
  2. J Clin Invest. 2007 Mar;117(3):514-21 [PMID: 17332878]
  3. Autoimmunity. 2007 Nov;40(7):512-20 [PMID: 17966041]
  4. Anal Biochem. 1976 May 7;72:248-54 [PMID: 942051]
  5. Int J Biochem Cell Biol. 2007;39(1):44-84 [PMID: 16978905]
  6. Dig Dis Sci. 1992 Jun;37(6):818-26 [PMID: 1587185]
  7. Inflamm Bowel Dis. 2010 Sep;16(9):1467-75 [PMID: 20186929]
  8. Biochem Biophys Res Commun. 2003 Aug 1;307(3):547-52 [PMID: 12893257]
  9. Inflamm Bowel Dis. 2006 Apr;12(4):304-10 [PMID: 16633052]
  10. Methods Enzymol. 1984;105:121-6 [PMID: 6727660]
  11. Biol Trace Elem Res. 2009 Dec;132(1-3):27-34 [PMID: 19436958]
  12. Klin Wochenschr. 1991 Dec 15;69(21-23):965-8 [PMID: 1798292]
  13. Gastroenterology. 2004 May;126(6):1504-17 [PMID: 15168363]
  14. Exp Physiol. 1997 Mar;82(2):291-5 [PMID: 9129943]
  15. Free Radic Biol Med. 1995 Apr;18(4):815-21 [PMID: 7750804]
  16. Inflamm Bowel Dis. 2009 Jan;15(1):93-9 [PMID: 18626964]
  17. Scand J Gastroenterol. 2001 Dec;36(12):1289-94 [PMID: 11761019]
  18. Hepatogastroenterology. 2000 Jul-Aug;47(34):1015-7 [PMID: 11020867]
  19. Curr Gastroenterol Rep. 2008 Dec;10(6):568-75 [PMID: 19006613]
  20. Clin Exp Immunol. 1993 Oct;94(1):174-81 [PMID: 8403503]
  21. Scand J Rheumatol. 2010 May;39(3):247-53 [PMID: 20429675]
  22. J Biol Chem. 1993 Jul 25;268(21):15405-11 [PMID: 8393440]
  23. Anticancer Agents Med Chem. 2011 Feb;11(2):178-80 [PMID: 21291402]
  24. Nat Rev Immunol. 2008 Jun;8(6):458-66 [PMID: 18500230]
  25. Mt Sinai J Med. 2006 Dec;73(8):1067-73 [PMID: 17285196]
  26. Biol Trace Elem Res. 2010 Oct;137(1):13-22 [PMID: 19898754]
  27. J Physiol Pharmacol. 2011 Feb;62(1):65-73 [PMID: 21451211]
  28. Free Radic Res. 2012 Feb;46(2):141-6 [PMID: 22126431]
  29. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e271-5 [PMID: 22738420]
  30. Saudi J Gastroenterol. 2007 Oct-Dec;13(4):187-90 [PMID: 19858644]
  31. Science. 1983 Sep 23;221(4617):1256-64 [PMID: 6351251]
  32. Clin Biochem. 2002 Oct;35(7):569-72 [PMID: 12493587]
  33. Am J Gastroenterol. 2003 Feb;98(2):348-53 [PMID: 12591053]
  34. Free Radic Biol Med. 1994 Sep;17(3):235-48 [PMID: 7982629]
  35. World J Gastroenterol. 2005 Apr 28;11(16):2371-84 [PMID: 15832404]
  36. Clin Microbiol Rev. 2002 Jan;15(1):79-94 [PMID: 11781268]
  37. Int J Mol Sci. 2013 Feb 05;14(2):3265-84 [PMID: 23385234]
  38. Dis Mon. 2006 May;52(5):199-207 [PMID: 16828361]
  39. Life Sci. 2003 Aug 15;73(13):1655-66 [PMID: 12875898]
  40. Inflamm Bowel Dis. 2008 Dec;14(12):1660-6 [PMID: 18623174]

MeSH Term

Adolescent
Adult
Aged
Aged, 80 and over
Antioxidants
Biomarkers
Case-Control Studies
Catalase
Female
Humans
Inflammatory Bowel Diseases
Intestinal Mucosa
Lipid Peroxidation
Male
Malondialdehyde
Middle Aged
Oxidative Stress
Sulfhydryl Compounds
Tunisia
Young Adult

Chemicals

Antioxidants
Biomarkers
Sulfhydryl Compounds
Malondialdehyde
Catalase

Word Cloud

Created with Highcharts 10.0.0biopsiesIBDCrDUCstresscomparedpatients'diseaseinflammatoryfactorsintestinalMDACDlevelscontrols'P0bowelincludingreactiveoxidativeproteinTunisianthiolCATactivitypatients12Oxidativesignificantlyincreased>05BACKGROUND/AIMS:InflammatorydiseasesIBDsCrohn'sulcerativecolitischronicgastrointestinaldisorderspreciseetiologyremainsunclearthoughtinteractionsamongvariousgenetichostimmunesystemenvironmentalcausedisruptionhomeostasisleadingdysregulatedresponsesgutinflammationintimatelyrelatedformationintermediatesoxygenspeciesproposedmechanismunderlyingpathophysiologypurposestudyexaminelipidperoxidationoxidationanti-oxidativeprofileMATERIALSANDMETHODS:Malondialdehydeconjugateddieneswellcatalaseevaluated17affected5healthycontrolindividualsRESULTS:confirmedtwotypescontrols<001similarbiopsies'Anon-significantdecreaseSHlevelobservedCONCLUSION:Increasedunderlineimplicationphysiopathologymarkersmucosa

Similar Articles

Cited By